Evidence map›Paper›PMID 33969529›Full record

ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2022

Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections.

Caroline Struijk, Wouter Van Genechten, Peter Verdonk, Aaron J Krych, Allan B Dietz, Andre J van Wijnen, Daniel B F Saris

Open access · hybridAbstract read
In one paragraph

Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 4 countries.

Caroline StruijkOrthopedics and Sports Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0203-607X
Wouter Van GenechtenOrthopedics and Sports Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5844-9247
Peter VerdonkDepartment of Orthopedic Surgery, Antwerp University, Antwerp, Belgium.
Aaron J KrychOrthopedics and Sports Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Allan B DietzDepartment of Laboratory Medicine and Pathology, IMPACT; Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Andre J van WijnenOrthopedics and Sports Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4458-0946
Daniel B F SarisOrthopedics and Sports Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity of Antwerp · BE

Funding

Molecular Control of Bone FormationR01AR049069 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WESTENDORF, JENNIFER J · 2003 to 2021
$5.8M
NIAMS NIH HHS R01 AR049069
6 · The paper itself

Abstract

Meniscus allograft transplantations (MATs) represent established surgical procedures with proven outcomes. Yet, storage as frozen specimens and limited cellular repopulation may impair graft viability. This proof-of-concept study tests the feasibility of injecting allogeneic mesenchymal stromal/stem cells (MSCs) in meniscus allograft tissue. We investigated the injectable cell quantity, survival rate, migration, and proliferation ability of MSCs up to 28 days of incubation. In this controlled laboratory study, seven fresh-frozen human allografts were injected with human allogeneic MSCs. Cells were labeled and histological characteristics were microscopically imaged up to 28 days. Mock-injected menisci were included as negative controls in each experiment. Toluidine blue staining demonstrated that a 100-µl volume can be injected while retracting and rotating the inserted needle. Immediately after injection, labeled MSCs were distributed throughout the injection channel and eventually migrated into the surrounding tissues. Histological assessment revealed that MSCs cluster in disc-like shapes, parallel to the intrinsic lamination of the meniscus and around the vascular network. Quantification showed that more than 60% of cells were present in horizontally injected grafts and more than 30% were observed in vertically injected samples. On Day 14, cells adopted a spindle-shaped morphology and exhibited proliferative and migratory behaviors. On Day 28, live/dead ratio assessment revealed an approximately 80% cell survival. The study demonstrated the feasibility of injecting doses of MSCs (>0.1 million) in meniscus allograft tissue with active cell proliferation, migration, and robust cell survival.

Indexed as

Hematopoietic Stem Cell TransplantationMeniscusMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAllograftsHumansTransplantation, Homologousallograftkneemeniscusmesenchymal stromal cellviability

Identifiers

PMID33969529
PMCPMC8578587
OpenAlexW3163565119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.